Pfizer Inc. (NYSE:PFE) is one of the 13 Best Large Cap Stocks to Buy Right Now. On July 10, Pfizer Inc. (NYSE:PFE) shared ...

Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety ...

Pfizer is facing significant revenue and earnings declines, primarily due to patent expirations of leading drugs. See why I still rate PFE stock a strong buy.

Pfizer's earnings and sales have fallen due to decreased demand for COVID-19 products. Click here to read why PFE's pipeline may offer upside potential.

Pfizer (NYSE: PFE) stock price has crashed hard in the past few years as demand for Covid-19 vaccines faded globally. It was trading at $28 on Monday, down from the pandemic high of $55.56. It has ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report ...

PFIZER INC (PFE) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 95% based on the firm’s underlying fundamentals and the stock’s valuation.

The US stock market bounced back on Tuesday after the truce between Iran and Israel. The Dow Jones, Nasdaq 100, and S&P 500 indices jumped by over 1%, and the bullish momentum continued in the futures ...

Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely reflecting existing concerns.

Pfizer's COVID-19 product revenue is sinking. Even in a worst-case scenario, though, Pfizer's valuation is much cheaper than its peers. The stock looks like a no-brainer pick for two kinds of ...

Pfizer 's (PFE 0.30%) management team is confident in its 2025 opportunities. *Stock prices used were the afternoon prices of May 20, 2025. The video was published on May 22, 2025.